Clinical trials have tested immunotherapy for dormant cancer cells, perioperative β-adrenoreceptor blockade, COX-2 inhibition, psychophysiological approaches to reduce the prometastatic process and cancer reawakening, and antioxidants and differentiating agents to maintain dormancy. The gene discussed is PTGS2; the disease is cancer.